

Annual Report and Accounts

2018-19



www.sruk.co.uk

Charity Registration Number: 1161828

CONTENTS

Overview

Message from Chair and Chief Executive	2
--	---

Trustees' Report

Our Vision, Purpose & Values	3
Our Strategic Aims	3
What we did in 2018-19	3
• Awareness	3
• Empowerment	4
• Healthcare	5
• Research	5
Financial Review	6
Principal Risks & Uncertainties	8
Structure, Governance & Management	8
Statement of Trustees' responsibilities	9

Independent Auditor's Report	10
-------------------------------------	-----------

Financial Statements

Consolidated Statement of Financial Activities	12
Consolidated and Charity Balance Sheets	13
Consolidated Cash Flow Statement	14
Notes to the Consolidated Financial Statements	15
Legal and Administrative Information	29

OVERVIEW

Message from Chair & Chief Executive

2018-19 was another busy year for SRUK, working hard with our community of supporters, clinicians and researchers to deliver on the second year of our five-year strategy. We are delighted to report that this hard work is paying off.

We've seen real growth in terms of our reach and engagement with a three-fold increase in web users and an increase in social media followers, from 4,450 to 34,430, since SRUK went live 3 years ago.

Our supporter base has grown from 1,897 to over 9,000, helping to reverse the decline in income experienced by the pre-merger organisations. From a base of half a million, there is a clear plan in place to grow our annual income substantially over the next three to five years.

We are very clear about the challenges that face our community and the outcomes people with Scleroderma and Raynaud's want SRUK to achieve.

We are continuing our work to raise awareness about the signs and symptoms of both Scleroderma and Raynaud's. Using novel approaches, such as the online Raynaud's test, helped us secure coverage on BBC Breakfast, as well as across a wide range of radio and press across the UK. Over 45,000 people have taken the test since we launched it in 2017, with 96% receiving a response of Raynaud's and 19% were advised to see their GP for further testing.

We continue to contribute to a range of consultations, such as the assessment of rare disease treatments across all appraisal and reimbursement processes, and we've campaigned with others to secure recognition for non-genetic rare diseases within the UK Strategy for Rare Diseases.

Last year we produced updated publications on Understanding Raynaud's and Understanding Scleroderma and a new Annual Tests booklet. We continue to provide information and support through our social media channels, with our posts reaching over 2.3 million people.


We know that finding a cure and increasing our investment in research are key priorities for our community. Over the last year we worked hard to broker collaborations to bring in additional funds for research into Scleroderma and Raynaud's. Alongside awarding four new research grants worth £141,000, we brokered partnerships with a number of external agencies.

This includes working with the World Scleroderma Foundation on a joint funding call and a joint Research Fellow with the Medical Research Council during 2019-20. We also secured support from Insilico Medicine, a US based company applying artificial intelligence to drug discovery and biomarker development, which will enable us to work with them in the next financial year, hopefully to identify new drug compounds.

None of the work we do would be possible without the generosity of our supporters. We truly appreciate how hard earned these donations are and we want to ensure we continue to invest in the best projects and research and where possible turn some of this investment into new income streams.



Professor Jeremy Pearson
Chair of Trustees



Sue Farrington
Chief Executive

TRUSTEES' REPORT

Our Vision

A world where no-one has their life limited by Scleroderma and Raynaud's.

Our Purpose

Our mission is to improve the lives of everyone affected by Scleroderma and Raynaud's. We do this by investing in research, improving awareness and understanding of the conditions and providing information and support to all those affected.

Our Values

Our values inform how we deliver our services, the choices we make and how we work with, support and develop our staff and volunteers.

SRUK is:

Collaborative in the way we work.

Driven to see real change.

Trusted because we are open and honest about the way we work.

Compassionate because we always put the person first.

Our Strategic Aims - 2017-2022

Awareness

Increase awareness of Scleroderma and Raynaud's with the public and health professionals.

Empowerment

Enable more people with Scleroderma and Raynaud's to manage their conditions through access to high quality information, support and guidance.

Healthcare

Ensure all people with Scleroderma and Raynaud's across the UK have access to high quality, integrated health and social care services, which are responsive to their needs.

Research

Ensure that research funded by SRUK translates into better prevention, diagnosis and treatment outcomes.

Infrastructure

Be an effective and efficient organisation, with the resources we need to achieve our goals.

What we did in 2018/2019

SRUK's current strategy for 2017-2022, which is informed and shaped by the challenges and needs of our community, has given us a good framework and clear direction of travel for our work. 2018-19 was its second year of delivery and we have reported below on the progress we have made during this period towards achieving our goals.

AWARENESS

The lack of awareness and understanding across public and professionals has led to poor support and treatment of Raynaud's and delayed diagnosis of Scleroderma. Raynaud's is to date the only known clinical manifestation considered to be a risk factor for developing Scleroderma.

The condition of Raynaud's is poorly understood. It is not treated seriously by many professionals and consequently we do not know exactly how many people are affected or how severely it affects them. As a result, many are going undiagnosed with severe Raynaud's and Scleroderma. This has serious, life threatening consequences for people with Scleroderma.

In 2018-19 we:

1. Continued our work to increase awareness using novel approaches, such as the online Raynaud's test, to help us secure media coverage on radio and press. The online test was developed with the support of three consultant rheumatologists specialising in Scleroderma and Raynaud's ensuring this tool follows the clinical diagnosis pathway, giving users a trusted result. Users of the test answer five simple yes or no questions and receive a result as to whether they may have Raynaud's or not. Further information is provided to users who may have Raynaud's including self-management information. Those identified as at risk of having an underlying condition are encouraged to see their GP.

In February 2019 we secured coverage on BBC Breakfast, with a feature piece on severe Raynaud's and a live interview with the CEO, which led to over 10,000 people taking the online test. On radio we reached over 8 million listeners during prime-time hours, featuring on BBC Radio Wales, British Forces Broadcasting Service (BFBS), 10 Regional BBC Radio Stations and 13 local commercial & community stations.

Over 45,000 people have taken the test since we launched it in 2017, with 96% receiving a response of Raynaud's and 19% were advised to see their GP for further testing. The results

TRUSTEES' REPORT

from the survey informed a research paper, written by Dr Mike Hughes and Dr John Pauling, which was published in the Annals of Rheumatic Disease – 'Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groups'.

2. Produced an animation explaining Scleroderma to support our #KnowScleroderma campaign for Scleroderma Awareness Month, which had over 31,000 views and reached 108,000 people. The animation was well received by the community who said that it provided a useful tool to help explain their condition to family and friends.

The overall aim of the campaign was to increase awareness and understanding of the signs and symptoms of Scleroderma to help improve time to diagnosis. This is based on research showing that people with Scleroderma are having to wait at least three years and have more than five appointments with their GP before getting a diagnosis.

Alongside working with national and regional press, we had a big radio push at the beginning of June to raise awareness of the condition across the UK. We did live interviews with 25 radio stations, featuring a representative from SRUK and someone with Scleroderma who shared her own very powerful story.

3. Involved an increasing number of members from our community; supporting them to share their own personal stories of living with Scleroderma and Raynaud's. Over the course of the year we worked with 25 people to become ambassadors to help support our awareness campaigns.
4. Built a wider profile for SRUK with professional audiences giving interviews and speaking on the topic of patient engagement and patient empowerment. These included:
 - A podcast on the importance of embedding healthcare information into the service pathway on the British Medical Journal's website which received over 5,000 hits.
 - An article for the Health Management Journal on the importance of embedding high-quality healthcare information throughout care pathways and the need for leadership teams to take up the challenge.
 - A feature in Pharmaphorum on how pharma and advocacy groups must work together if new hopes are to be realised, as part of their

listening to the patient voice series.

- Presentation at the House of Commons on patient empowerment to the All-Party Parliamentary Group for Healthcare.

What we aim to do:

- Develop and deliver a series of public awareness campaigns.
- Develop a network of advocates and ambassadors to share information about the conditions with those affected, the healthcare community and the general public.
- Work with the media to improve coverage and reporting of Scleroderma and Raynaud's.
- Work with health professional bodies and organisations to increase awareness of these conditions.

EMPOWERMENT

We want to ensure that everyone with Scleroderma and Raynaud's has access to the information and support they need to understand their condition and help better manage their symptoms. To achieve our aim of empowering our community and being inclusive we work across all channels: print, online, phone and face to face events.

In 2018-19 we:

1. Generated significant growth in terms of our reach and engagement with a threefold increase in web users. We continued to disseminate expert information and provide support through our social media channels. Our Facebook community grew by 17% to 9,487 and our Twitter community by 56% to 3,079, with our posts reaching over 2.3 million people.
2. Produced three new publications. The first two, Understanding Scleroderma and Understanding Raynaud's to provide the most up to date, evidence-based information on the conditions. They were reviewed by our clinicians and patients in line with our best practice to meet quality standards for healthcare information. The third publication was produced to inform patients about the Annual Tests that should be available to them to help monitor the progress of the condition.
3. Undertook an exercise to fully understand the needs of our diverse community, interviewing people living with the conditions and their loved ones. This work has led to a prioritisation of the development of key services which will be

TRUSTEES' REPORT

underway in the following year, including the development of a support group network.

4. Held our Annual Patient Information Conference in Windsor with an attendance of 150 patients from across the country and presentations from senior specialist clinicians in the UK. 100% rated the event good/very good/excellent and over 85% said practical workshops would help them better self-manage.
5. Received over 800 calls to our Helpline, run by our dedicated team of volunteers living with the condition.

HEALTHCARE

We want to ensure that everyone with Scleroderma and Raynaud's, wherever they live and whatever their circumstances, gets the responsive and person-centred support they need. We are working in collaboration with a wide range of agencies to drive local service improvement to ensure timely access to the appropriate professional and early access to treatment.

In 2018-19 we:

1. Visited 6 clinics as part of our programme to work more closely with the NHS and healthcare professionals to ensure our information is available at the point of diagnosis. To promote our services to people locally we have placed our information booklets in 15 general and specialist rheumatology clinics across the UK.
2. Continued to work with the Rare Auto-Immune Rheumatic Disease Alliance (RAIRDA), of which SRUK is a founder member, on progressing the delivery of the recommendations to reduce delays in diagnosis, improve the coordination of care and improve access to broader support and services. The recommendations were the outcome of the "State of the Nation" report based on feedback from a patient survey across rare auto-immune conditions.
3. Contributed to a range of consultations to ensure the voice of those with Scleroderma and Raynaud's is represented. These included:
 - initial documentation from NICE on the possible use of Tocilizumab to treat Scleroderma.
 - consultation on assessment of rare disease treatments across all appraisal and reimbursement processes, both NHS and NICE.
 - proposed Single Technology Appraisal for Nintedanib for treating interstitial lung disease in Scleroderma.

4. Lobbied for improvements in access to treatments, working with the Specialised Healthcare Alliance (SHCA) on the creation of 'patient impact reports' to accompany the clinical data presented to the Clinical Priorities Advisory Group (CPAG). The objective is to provide a mechanism for patient organisations to provide qualitative evidence of the burden of the condition to inform CPAG's deliberations. This would otherwise not be possible due to the current restrictions on the forms of data that can be considered.

RESEARCH

Increasing our investment in research is a priority for our community. We want to ensure that the research we fund translates into better prevention, diagnosis and treatment outcomes. To achieve our ambition we worked with patients, clinicians and researchers.

In 2018-19 we:

1. Established the SRUK Community Research Panel of a range of patients living with Scleroderma and/or Raynaud's to identify the key research priorities within the research strategy.
2. Convened the SRUK Strategy Advisory Group of senior leaders within the life sciences industrial landscape and autoimmune rheumatological research to provide guidance and direction on the research strategy.
3. Developed an innovative five-year research strategy designed to accelerate the benefits of research to patients sooner rather than later, focusing on early detection, precision medicine, quality of life and cause of the conditions.
4. Joined forces with the World Scleroderma Foundation to launch a jointly funded research call on 'Improving treatment outcome measures', which will be awarded in 2019-20.
5. Secured a jointly funded fellowship with the Medical Research Council to support the careers of promising researchers, which will be announced in 2019-20.
6. Secured a partnership with Insilico Medicine, a biotechnology company utilising artificial intelligence to identify potential therapeutics, which will report on their findings in the next financial year.
7. Partnered with D4T4, a company specialising in data capture and analysis, through the successful bid for a grant from Microsoft's AI

TRUSTEES' REPORT

(artificial intelligence) for Good programme, to explore the collection of data to enable earlier detection of Scleroderma.

8. Supported 13 ongoing grants, and awarded 4 new grants
 - Dr Angela Tam; Royal Free Hospital/University College London “Profiling of subpopulations of monocytes and monocyte-derived cells in scleroderma to identify targets for biomarker, patient stratification and therapy”.
 - Dr Clare Pain; Alder Hay Children’s Hospital b“Elicitation of expert prior opinion for a future Bayesian randomised controlled trial for Juvenile Localised Scleroderma (JLS)”.
 - Dr Francesco del Galdo; University of Leeds “Preclinical pathologic signs of systemic sclerosis in Raynaud’s patients at risk of Scleroderma”.
 - Dr Richard Stratton; Royal Free Hospital/ University College London: “Using microneedle patches to administer novel anti-fibrotic peptides in order to treat Scleroderma”.

WHAT WE WILL DO IN 2019-20:

For our work in Awareness, we will:

Continue to deliver a series of public awareness campaigns around our two campaign peaks, the Scleroderma Awareness Campaign in June and Raynaud’s Awareness Month in February.

Strengthen our network of journalists and build relationships with the medical and science press to maintain our position as the organisation for information and comment on matters relating Scleroderma and Raynaud’s.

Expand our network of patient ambassadors, supporting them to share their stories and act as ambassadors with local and regional media, to increase awareness about the conditions.

For our work in Empowerment, we will:

Continue to produce information on the conditions and what people can do to self-manage their condition.

Refine our customer feedback mechanisms to measure the value and quality of our information.

Develop and implement a plan based on the recommendations from consultations with our community regarding their support needs.

Further develop our social media networks for those affected by the conditions, based on insights into audience behaviours to identify content needed.

For our work in Healthcare we will:

Continue to work with the NHS and healthcare professionals to ensure information is available, particularly at point of diagnosis

Continue our programme to establish SRUK presence in all clinics through key literature and visits

Work with RAIRDA to drive forward the recommendations arising from the Patient Survey report key organisations to ensure voice of Scleroderma & Raynaud’s is represented

Support the development of an audit to monitor the implementation of best practice guidelines for the management and treatment of Scleroderma.

For our work in Research we will:

Continue to involve patients in our research programme to put their needs at the heart of the work we do.

Hold an multi stakeholder workshop SRUK to explore the development of diagnostic tools, biomarker manufacturing and novel therapies.

Begin the implementation of the five-year research strategy to ensure we make the most effective use of the charity’s limited resources.

FINANCIAL REVIEW

This report covers the period 1 April 2018 to 31 March 2019.

Overview

2018-19 was our third full year of operation after the merger and income for the year was largely in line with our budget.

Our focus has continued to be to increase and diversify our fundraising and achieve a step change in our impact, effectiveness and efficiency. We have fully committed to a long-term approach towards financial planning and of investment in key areas.

We have also sought to invest significant amounts of the surplus generated in 2017-18 into our work programme for the year to drive forward with our focus on improving impact and our reach to directly benefit people affected by Scleroderma and Raynaud’s. As a result, we posted a deficit of £151,568.

TRUSTEES' REPORT

How we raised our money

Key income streams for the charity comprise: Membership; Donations; Legacies; Trading and Fundraising Activities. In 2018-19 the total fundraising income for the group was £541,384.

We received £521,961 in donations and legacies; £11,241 from investments; and £8,182 from membership and conference activities.

The trading subsidiary of the charity brought in revenues of £46,388.

SRUK is registered with the Fundraising Regulator and is a member of the Institute of Fundraising. Our fundraising is carried out by a team of professional fundraisers based in our London headquarters, together with volunteers in their local communities. The team's activities are supervised by the Senior Management Team and follow recommended fundraising codes of practice. We did not receive any complaints about our fundraising activities in 2018-19.

How we spent our money

During 2018-19 our total charitable expenditure came to £559,775, an increase on the previous year.

This expenditure included £232,496 spent on Research. We also invested in the development of a range of services:

- Provision of information and support across all channels – print, online, phone and events. This included the development of the website and online platforms.
- Raising awareness of Scleroderma and Raynaud's with health care professionals and public.
- Establishing our campaigning & advocacy work through partnerships & alliances.
- Developing our infrastructure to ensure our organisation is efficient, effective and complies with all legal and regulatory requirements.

Balance Sheet

As at 31 March 2019, total funds were £1,903,479 for the Group and £1,906,087 for the Charity.

Reserves Policy

The Trustee Board has specified a reserves policy, which ensures that the Charity has sufficient funds to meet the cost of its day to day activities and is able to cope with the financial impact of unforeseen

events. In addition, where possible funds should be set aside to meet future planned expenditure. These reserves are known as the Operating Reserves.

Operating Reserves

The charity should hold sufficient financial reserves to ensure it can continue to operate in the event of unforeseen and potentially financially damaging circumstances arising.

The Board agreed that this amount should be equivalent to a minimum of six months' operating expenditure, which would amount to Operating Reserves of close to £373,000 in the current year as against the current free reserves of the Group at £594,757 and Charity at £597,365. The Board feels that the current level of reserves is adequate but not excessive.

Investment Policy

Rathbones Investment Management Limited continue as SRUK's investment managers. Over the year the value of these investments increased to £525,259.

The investment manager reports on a quarterly basis on the performance of the investments under management. These reports are incorporated into the quarterly management accounts and the year-end accounts of the Charity and reviewed by the Trustees at the quarterly board meetings.

The Board of Trustees carries out an annual review of the investment principles under which the manager operates and hold an annual review of the performance with the investment manager.

Grants Policy

Grants are accounted for fully in the year they are awarded in accordance with SORP requirements. They are therefore treated as liabilities in the accounts in the year they are awarded.

Trading Subsidiary

Over 2018-19 SRUK's trading subsidiary brought in £46,388 of income.

Just over £5,000 of staff costs were paid back to the charity for the running of the shop, bringing total expenditure to £43,804. We continue to improve the technical and online capability of the shop as well as its operational efficiency and staff support costs. We expect the shop to continue to be profitable.

TRUSTEES' REPORT

Going Concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.

Principal Risks and Uncertainties:

SRUK is committed to effective risk management as an integral part of ensuring good corporate governance. Informed risk-taking helps to improve performance, manage our threats and opportunities and to create an environment of 'no surprises'. This will enable us to get the right balance between innovation and change.

As a relatively new charity, we are reviewing and strengthening our risk management processes, to enable us to conclude whether major risks have been identified and reviewed.

Key principal risks identified include the need for:

- Clear strategic direction
- Sufficient financial resources

To help mitigate these risks, SRUK has implemented various initiatives, including the development of a five-year strategy, based on key outcomes from the organisation's theory of change developed in May 2016.

SRUK has implemented an annual financial budget and operational plan aimed at managing financial risks and progressing the strategic plan. These are monitored on a quarterly basis by the Board.

A fundraising strategy outlines how SRUK will raise the money to meet its strategic goals.

SRUK has opted for an audit, despite falling below the minimum requirement threshold, to ensure SRUK's processes and systems are robust and secure.

Structure, governance and management

Scleroderma & Raynaud's UK is a Charitable Incorporated Organisation, registered charity number: 1161828

SRUK is governed by its Constitution.

The principal objects of the charity and the group are:

(i) to relieve persons suffering from Raynaud's and Scleroderma (Systemic Sclerosis), including the provision of financial support for such persons and their families in need;

(ii) to advance the education and awareness of the public and health professionals in all aspects of Raynaud's and Scleroderma, including the provision and production of educational literature on these disorders; and

(iii) to provide financial support for research into the cause, treatment, care and prevention of both Raynaud's and Scleroderma and the dissemination of the results of such research for the public benefit.

Method of appointment or election of Trustees

The management of the charity and the group is the responsibility of the Trustees who are elected and co-opted under the terms of the SRUK Constitution, registered with the Charity Commission on 26 May 2015.

Merger

The merger between the Raynaud's & Scleroderma Association and The Scleroderma Society to form SRUK occurred during 2015-16. The Charity Commission approved the formation of the new CIO named "Scleroderma & Raynaud's UK" in May 2015. Following this all staff and assets were transferred from The Scleroderma Society and Raynaud's & Scleroderma Association into SRUK.

Since SRUK launched, both The Scleroderma Society and Raynaud's & Scleroderma Association continue to exist as dormant inactive charities. This is to ensure that any funds that may be donated to either organisation can be received and then passed on to SRUK so we can continue our vital work.

Organisational structure and decision making

The Trustees who served during the year are set out on page 29. The Trustees have been selected for their expertise and professional skills. They meet quarterly with the Chief Executive.

Peer reviewers are invited to assist with the review of grant applications made to SRUK and their recommendations are reported back to the Trustees who then approve or reject grant applications on merit or on the funding available. In 2016/17 a Research sub-committee was established to bring further rigour to the process.

Key Management Remuneration

SRUK is committed to a policy of equal pay and aims to ensure that salaries reflect the knowledge, skills, behaviours and capabilities required for satisfactory performance in each role whilst also demonstrating appropriate use of charitable donations. Salaries are benchmarked against the voluntary sector and where appropriate, other relevant job markets. Remuneration for key management personnel is handled in the same way as for all other staff.

TRUSTEES' REPORT

Public Benefit

We have considered the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and planning future activities. The Trustees always ensure that the activities undertaken are in line with the charitable

objectives and aims of SRUK.

As highlighted in this report, some of our research grants are specifically targeted at trying to determine the cause of Scleroderma and Raynaud's, thereby helping the general population in finding better treatments in the future.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year and Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period.

In preparing these financial statements, the Trustees are required to:

- Select the most suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgments and accounting estimates that are reasonable and prudent.
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them

to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and ensuring their proper application under charity law and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as each of the Trustees is aware:

- there is no relevant audit information of which the charitable company's auditor are unaware
- the Trustees have each taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Board of Trustees on 21st January 2020 and signed on their behalf by:



..... Chris Coombe, Treasurer

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF SCLERODERMA & RAYNAUD'S UK

Opinion

We have audited the financial statements of Scleroderma & Raynaud's UK for the year ended 31 March 2019 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Cash Flow Statement and notes to the consolidated financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and of the parent charity's affairs as at 31 March 2019 and of the group's net movement in funds for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder. We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Trustees for the financial statements

As explained more fully in the Trustees' responsibilities statement set out on page 9, the Trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the group's and the parent charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the group or the parent charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF SCLERODERMA & RAYNAUD'S UK

- the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the Trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the group's or the parent charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees' Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charity; or
- sufficient accounting records have not been kept; or
- the parent charity financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's Trustees as a body for our audit work, for this report, or for the opinions we have formed.

Haysmacintyre LLP

21st January 2020

Haysmacintyre LLP
Statutory Auditor,
10 Queen Street Place,
London EC4R 1AG

Haysmacintyre LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

SCLERODERMA & RAYNAUD'S UK
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2019

	Notes	General Funds 2019 £	Restricted Funds 2019 £	Total Funds 2019 £	General Funds 2018 £	Restricted Funds 2018 £	Total Funds 2018 £
INCOME FROM:							
Donations and legacies	5	521,961	-	521,961	1,501,449	59,461	1,560,910
Investments	7	11,241	-	11,241	11,295	-	11,295
Membership and conferences	6	8,182	-	8,182	13,780	-	13,780
Total fundraising income		541,384	-	541,384	1,526,524	59,461	1,585,985
EXPENDITURE ON:							
Raising funds: donations and legacies	9	(142,843)	-	(142,843)	(115,400)	-	(115,400)
Total fundraising expenditure		(142,843)	-	(142,843)	(115,400)	-	(115,400)
Fundraising contribution		398,541	-	398,541	1,411,124	59,461	1,470,585
Trading income	8	46,388	-	46,388	57,351	-	57,351
Trading expenditure	8	(43,804)	-	(43,804)	(55,818)	-	(55,818)
Contribution from trading activities		2,584	-	2,584	1,533	-	1,533
Net income available for charitable purposes		401,125	-	401,125	1,412,657	59,461	1,472,118
Charitable expenditure							
Research	9	(232,496)	-	(232,496)	(126,228)	(48,985)	(175,213)
Services to members	9	(327,279)	-	(327,279)	(314,137)	(10,476)	(324,613)
Total charitable expenditure		(559,775)	-	(559,775)	(440,365)	(59,461)	(499,826)
Net (expenditure)/ income available for charitable purposes		(158,650)	-	(158,650)	972,292	-	972,292
Represented by							
Total income		587,772	-	587,772	1,583,875	59,461	1,643,336
Total expenditure		(746,422)	-	(746,422)	(611,583)	(59,461)	(671,044)
Net (expenditure)/ income before gain/ (loss) on investments		(158,650)	-	(158,650)	972,292	-	972,292
Net gain/(loss) on investments	14	7,082	-	7,082	(7,505)	-	(7,505)
Net (expenditure)/ income		(151,568)	-	(151,568)	964,787	-	964,787
Other recognised (losses)/gains							
Net (loss) on property revaluation	13	-	-	-	(50,000)	-	(50,000)
Net movement in funds		(151,568)	-	(151,568)	914,787	-	914,787
Reconciliation of funds							
Fund balances brought forward		2,055,047	-	2,055,047	1,140,260	-	1,140,260
Total funds carried forward	20	1,903,479	-	1,903,479	2,055,047	-	2,055,047

The charity has no recognised gains or losses other than the results for the year as set out above. All of the activities of the charity are classed as continuing.

**SCLERODERMA & RAYNAUD'S UK
CONSOLIDATED AND CHARITY BALANCE SHEETS
AS AT 31 MARCH 2019**

	Notes	Group 2019 £	Group 2018 £	Charity 2019 £	Charity 2018 £
FIXED ASSETS					
Tangible assets	13	150,231	150,463	150,231	150,463
Investments	14	525,259	511,790	525,259	511,790
		675,490	662,253	675,490	662,253
CURRENT ASSETS					
Stock	15	22,166	9,703	-	-
Debtors: amounts falling due within one year	17	169,268	1,175,747	194,564	1,213,834
Cash at bank and in hand		1,594,017	881,859	1,579,495	847,909
		1,785,451	2,067,309	1,774,059	2,061,743
CREDITORS:					
Amounts falling due within one year	18	(557,462)	(674,515)	(543,462)	(663,599)
NET CURRENT ASSETS					
		1,227,989	1,392,794	1,230,597	1,398,144
Total assets less current liabilities		1,903,479	2,055,047	1,906,087	2,060,397
NET ASSETS					
		1,903,479	2,055,047	1,906,087	2,060,397
CAPITAL AND RESERVES					
Restricted funds	19	-	-	-	-
Designated funds	20 & 21	1,308,722	1,450,000	1,308,722	1,450,000
Unrestricted funds	20 & 21	594,757	605,047	597,365	610,397
		1,903,479	2,055,047	1,906,087	2,060,397

These financial statements were approved and authorised for issue by the Board on the 21st January 2020 and are signed on their behalf by C Coombe



..... Chris Coombe, Treasurer

**SCLERODERMA & RAYNAUD'S UK
CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2019**

	2019 £	2019 £	2018 £	2018 £
Cash flows from operating activities				
Net income/(expenditure) for the year (as per the statement of financial activities)	(151,568)		914,787	
Adjustments for:				
Depreciation charges	232		337	
Dividends, interest and rents from investments	(11,241)		(11,295)	
Loss on the revaluation of fixed assets	-		50,000	
(Increase) in stocks	(12,463)		(2,465)	
(Increase) in debtors	1,006,479		(1,031,518)	
(Decrease)/increase in creditors	(117,053)		(100,199)	
	<hr/>		<hr/>	
Net cash provided by/(used in) operating activities		714,386		(180,353)
Cash flows from investing activities				
Dividends, interest and rents from investments	11,241		11,295	
Purchase of investments	(57,200)		(107,298)	
Sale of investments	50,813		100,713	
(Gains)/Losses on investments	(7,082)		7,505	
	<hr/>		<hr/>	
Net cash provided by/(used in) investing activities		(2,228)		12,215
Change in cash and cash equivalents in the year		712,158		(168,137)
Cash and cash equivalents at the beginning of the year		881,859		1,049,996
		<hr/>		<hr/>
Cash and cash equivalents at the end of the year		1,594,017		881,859

1. GENERAL INFORMATION

Scleroderma & Raynaud's UK ('the Charity' or 'SRUK') and its subsidiary (together "the Group") support the research of Raynaud's and Scleroderma diseases and offer advice and support to individuals suffering from the conditions throughout the UK.

Scleroderma & Raynaud's UK is a public benefit entity having registered charity number 1161828 and was incorporated in England. The address of its registered office is Bride House, 18-20 Bride Lane, London, EC4Y 8EE.

2. ACCOUNTING POLICIES

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective 1 January 2015) - (Charities SORP (FRS102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The SRUK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the Charity and its subsidiary undertaking being RSA Trading Company Limited. The results of the subsidiary are consolidated on a line by line basis after the elimination of intra-group transactions. Control has been obtained by the ownership of shares.

b) Going concern

The Trustees continue to monitor the performance of the charity against budgets and forecasts for the foreseeable future in the difficult economic climate. Given the net current asset position at the year-end, the Trustees consider it appropriate to prepare the financial statements on the going concern basis.

c) Fund Accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

d) Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). The general volunteer time of the friends is not recognised and refer to the Trustees' Report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
2. ACCOUNTING POLICIES (CONTINUED)**

facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

e) Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure is classified under the principal categories of charitable and other expenditure rather than the type of expense, in order to provide more useful information to users of the accounts.

Cost of raising funds are those incurred in seeking voluntary contributions, and those incurred in trading activities that raise funds but do not include the costs of disseminating information in support of the charitable activities.

Charitable activities comprise direct expenditure including direct staff costs attributable to the activity.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

Governance costs are those incurred in connection with the management of SRUK's assets, organisational administration and compliance with constitutional and statutory requirements.

Support and Governance costs are allocated on the basis of time spent on each activity.

Grants are accounted for fully in the year they are awarded in accordance with Charities SORP (FRS 102) requirements. They are therefore treated as liabilities in the accounts in the year they are awarded, where they have not been paid at the year end.

f) Tangible Fixed Assets

All assets costing more than £1,000 are capitalised.

Tangible fixed assets are carried at cost or valuation, net of depreciation and any provision for impairment. Depreciation is not charged on freehold land. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment	20% straight line
------------------	-------------------

g) Revaluation of tangible fixed assets

The charity has adopted the cost model whereby items of property, plant and equipment are measured at cost less any accumulated depreciation and any accumulated impairment losses.

h) Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading 'Gains/(losses) on investments' in the Statement of Financial Activities.

Subsidiary undertakings:

Investments in subsidiaries are valued at cost less provision for impairment.

i) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
2. ACCOUNTING POLICIES (CONTINUED)**

j) Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

k) Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered.

Prepayments are valued at the amount prepaid net of any trade discounts due.

l) Cash and cash equivalents

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m) Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

n) Financial Instruments

The Charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the Charity would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

o) Taxation

The charity is exempt from tax on its charitable activities.

p) Termination benefits

Settlement agreements are recognised in the period they are incurred.

3. JUDGEMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION UNCERTAINTY (CONTINUED)

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The charity makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

(i) Useful economic lives of tangible assets

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 13 for the carrying amount of the tangible fixed assets and note 2(f) for the useful economic lives for each class of assets.

(ii) Impairment of fixed assets

At regular intervals, and at least annually, management review the carrying value of tangible fixed assets to determine whether this fairly represents the recoverable amount from their use. The carrying value is compared to the recoverable amount, defined as the higher of:

- Value in use is calculated from expected earnings streams or savings from continued employment of the asset
- Realisable value on a disposal

(iii) Accrued grants payable

Using the accruals basis of accounting, grants payable are matched to the period or are reported when the expense occurs, not when the cash is paid.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019**

4. NET INCOME/(EXPENDITURE) FOR THE YEAR

Net expenditure for the year is stated after charging:

	Group		Charity	
	2019	2018	2019	2018
	£	£	£	£
Depreciation on owned assets	232	337	232	232
Auditor's remuneration	8,350	8,100	8,350	8,100

5. DONATIONS AND LEGACIES

	Unrestricted Funds 2019	Restricted Funds 2019	Total Funds 2019	Total Funds 2018
	£	£	£	£
Group & Charity				
Donations	320,729	-	320,729	283,758
Legacies	201,232	-	201,232	1,277,152
	521,961	-	521,961	1,560,910

£59,461 of donations received in 2018 were restricted. All other donations and legacies received in 2018 were unrestricted.

6. MEMBERSHIP AND CONFERENCE INCOME

	Unrestricted Funds 2019	Restricted Funds 2019	Total Funds 2019	Total Funds 2018
	£	£	£	£
Group & Charity				
Membership income	7,403	-	7,403	12,230
Conference income	779	-	779	1,550
	8,182	-	8,182	13,780

All membership and conference income received in 2018 were unrestricted.

7. INVESTMENT INCOME

	Unrestricted Funds 2019	Restricted Funds 2019	Total Funds 2019	Total Funds 2018
	£	£	£	£
Group & Charity				
Dividend income	7,069	-	7,069	6,807
Interest income	4,172	-	4,172	4,488
	11,241	-	11,241	11,295

All investment income received in 2018 was unrestricted.

8. TRADING ACTIVITIES

	Income/Direct Costs 2019	Support Cost Allocation 2019	Total 2019	Total 2018
	£	£	£	£
Group				
Trading income	46,388	-	46,388	57,351
Trading costs	(43,804)	-	(43,804)	(55,818)
Trading net profit	2,584	-	2,584	1,533
Contribution from trading activities	2,584	-	2,584	1,533

All trading activities income received in 2018 was unrestricted.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019

9. EXPENDITURE

2019	Grants £ (note 10)	Staff Costs £	Other Direct Costs £	Support Cost Allocations £ (note 11)	Total 2019 £
Group					
Expenditure on Raising Funds					
Cost of Raising Funds	-	67,009	49,420	26,414	142,843
Expenditure on Trading Activities					
Retail (100% trading sub)	-	5,136	38,668	-	43,804
Expenditure on Charitable Activities					
Research	141,278	65,588	-	25,630	232,496
Services to Members	-	160,698	103,781	62,800	327,279
Support Costs Allocated	-	28,587	86,257	(114,844)	-
Total Expenditure	141,278	327,018	278,126	-	746,422

PRIOR YEAR

Group	Grants £ (note 10)	Staff Costs £	Other Direct Costs £	Support Cost Allocations £ (note 11)	Total 2018 £
Expenditure on Raising Funds					
Cost of Raising Funds	-	54,884	37,573	22,943	115,400
Expenditure on Trading Activities					
Retail (100% trading sub)	-	8,526	47,292	-	55,818
Expenditure on Charitable Activities					
Research	113,466	43,531	-	18,216	175,213
Services to Members	-	150,850	110,635	63,128	324,613
Support Costs Allocated	-	20,319	83,968	(104,287)	-
Total Expenditure	113,466	278,110	279,468	-	671,044

10. GRANTS

Analysis of grant expenditure

Group & Charity	2019 £	2018 £
University College London	128,312	79,000
Alder Hay	13,610	-
Queen Mary	-	62,000
Write backs	(644)	(27,534)
	141,278	113,466

Of the total grants payable £141,922 relates to grants payable to institutions (2018: £141,000).

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019**

Grant commitments are as follows:

	2019	2018
	£	£
Group & Charity		
Grant commitments at 1 April	620,145	689,750
Awards made during year	141,922	141,000
Payments made during the year	(369,644)	(183,071)
Grants retracted	(644)	(27,534)
Grant commitments at 31 March	391,779	620,145

11. GOVERNANCE AND SUPPORT COSTS

	Total 2019	Total 2018
	£	£
Group & Charity		
Support & Governance:		
Support staff costs	23,132	14,831
Human resources	3,877	6,955
Facilities	17,905	19,395
Finance & legal	29,009	20,483
Office costs	22,663	17,455
Governance staff costs	5,455	5,488
Governance other costs	12,803	19,680
Total support and governance costs	114,844	104,287

12. STAFF COSTS

	Group		Charity	
Staff costs were as follows:	2019	2018	2019	2018
	£	£	£	£
Wages and salaries	289,682	230,450	284,546	221,924
Social security costs	25,381	20,273	25,381	20,273
Pension	3,928	975	3,928	975
Temporary staff	8,027	26,412	8,027	26,412
	327,018	278,110	321,882	269,584

The average number of employees during the year was as follows:

	2019	2018
	No.	No.
Staff	9	9

Employees receiving remuneration amounting to more than £60,000 were as follows:

	2019	2018
	No.	No.
Remuneration £70,000 - £79,999	1	1

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019**

During the year redundancy was paid to one employee £2,436 (2018: none).

The key management personnel of the charity comprise the Trustees and the senior management team as listed on page 29. The total amount of employee benefits (including employer pension contributions) received by key management personnel for their services to SRUK was £140,776 (2018: £159,632)..

TRUSTEES

None of the Trustees (or any person connected with them) received any remuneration during the year, and total expenses reimbursed to Trustees was £1,263 relating to four Trustees for traveling and other expenses (2018 - £985 for 4 Trustees).

13. FIXED ASSETS

Group	Freehold land and buildings £	Furniture and equipment £	Total £
Cost or valuation			
At 1 April 2018	150,000	1,684	151,684
Impairment	-	(525)	(525)
At 31 March 2019	150,000	1,159	151,159
Depreciation			
At 1 April 2018	-	1,221	1,221
Depreciation charge	-	232	232
Disposal	-	(525)	(525)
At 31 March 2019	-	928	928
Net Book Value			
At 31 March 2018	150,000	463	150,463
At 31 March 2019	150,000	231	150,231

Charity

Cost or valuation			
At 1 April 2018	150,000	1,159	151,159
At 31 March 2019	150,000	1,159	151,159
Depreciation			
At 1 April 2018	-	696	696
Depreciation charge	-	232	232
At 31 March 2019	-	928	928
Net Book Value			
At 31 March 2018	150,000	463	150,463
At 31 March 2019	150,000	231	150,231

Advice was taken from local estate agents as to the appropriate values for the freehold land and buildings.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019

14. FIXED ASSET INVESTMENTS

	2019 Total £	2018 Total £
Group & Charity Investments		
Market value of quoted investments at 1 April	487,813	456,821
Additions	57,200	107,298
Disposal proceeds	(52,133)	(68,801)
Net investment gain / (loss)	7,082	(7,505)
Market value of quoted investments at 31 March	499,962	487,813
Cash on deposit	25,297	23,977
Market value at 31 March	525,259	511,790
Historic cost at 31 March	519,658	510,992
Accumulated unrealised gain	5,601	798
Historic Cost Gains		
Net investment gain / (loss)	7,082	(7,505)
Movement on unrealised gain / (loss)	(4,049)	9,673
Realised gains based on historic cost	3,033	2,168

All the fixed asset investments are held in the UK.

Investments have been valued at market value at the balance sheet date.

	2019 £	2018 £
Investments are represented by:		
Cash	25,297	23,977
Equity	135,258	132,119
Fixed interest	159,038	156,439
Alternatives	66,845	78,622
Overseas	138,821	120,633
Total	525,259	511,790

15. STOCK

	Group		Charity	
Stock	2019 £	2018 £	2019 £	2018 £
Stock	22,166	9,703	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019

16. FINANCIAL INSTRUMENTS

	Group		Charity	
	2019	2018	2019	2018
	£	£	£	£
Financial instruments measured at amortised cost	1,754,810	2,045,763	1,718,653	2,006,013
Financial liabilities measured at amortised cost	549,736	666,474	538,017	655,320

Financial assets measured at amortised cost comprise bank and cash, trade debtors, other debtors and accrued income.

Financial liabilities measured at amortised cost comprise trade creditors, other creditors, accruals and grant commitments.

17. DEBTORS

	Group		Charity	
	2019	2018	2019	2018
	£	£	£	£
Due within one year				
Trade debtors	8,500	6,685	885	885
Amounts owed by group entities	-	-	46,940	45,626
Accrued income	136,085	1,151,565	136,085	1,151,565
Other debtors	16,208	5,654	2,188	5,654
Prepayments	8,475	11,843	8,466	10,104
	169,268	1,175,747	194,564	1,213,834

18. CREDITORS

	Group		Charity	
	2019	2018	2019	2018
	£	£	£	£
Due within one year				
Trade creditors	130,394	21,149	128,738	15,238
Deferred income	-	1,897	-	1,897
Taxes and social security	7,726	6,144	5,445	6,382
Accruals	27,563	25,180	17,500	19,937
Grant commitments	391,779	620,145	391,779	620,145
	557,462	674,515	543,462	663,599

DEFERRED INCOME:

Group and Charity	2019 £	2018 £
Opening balance	1,897	3,791
Income released in the year	(1,897)	(3,791)
Income deferred in the year	-	1,897
Closing balance	-	1,897

Deferred income relates to deferred membership subscriptions.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019**

19. RESTRICTED FUNDS

There was no restricted income or expenditure during 2018/2019

2018

Group & Charity	Funds brought forward £	Income £	Expenditure including gains and losses £	Funds carried forward £
Brian Norris appeal		54,461	(54,461)	-
Actelion		5,000	(5,000)	-
	-	59,461	(59,461)	-

During the prior year part of Actelion's grant of £5,000 was used to hold a memorial lecture for Anne Mawdsley in the House of Commons (£3,000) and the remaining £2,000 was used to support the Annual Conference.

The Brian Norris donation of £54,461 was used to fund a number of key projects:

- £14,985 funded two midline machines at PITU in the Royal Free Hospital, London giving patients choice as to how they receive vital Iloprost infusions.
- £19,000 was used to fund a key research project led by Professor Chris Denton at the Royal Free Hospital looking into the Modulation of systemic sclerosis pathobiology by purified Factor XIII.
- £15,000 funded an important research project led by Professor Peter Butler, Royal Free, London on the mechanistic study of autologous lipotransfer in Systemic Sclerosis.
- £5,476 will fund a publication on Scleroderma to be made available in clinics across the UK, supported by a series of 4 videos with Professor Denton to be shown on the website and YouTube.

20. UNRESTRICTED FUNDS

2019

	Funds brought forward	Income	Expenditure including gains and losses	Transfer	Funds carried forward
GROUP	£	£	£	£	£
Designated	1,450,000	-	(141,278)	-	1,308,722
General	496,681	587,772	(598,062)	-	486,391
Revaluation	108,366	-	-	-	108,366
	2,055,047	587,772	(739,340)	-	1,903,479

	Funds brought forward	Income	Expenditure including gains and losses	Transfer	Funds carried forward
CHARITY	£	£	£	£	£
Designated	1,450,000	-	(141,278)	-	1,308,722
General	502,031	546,363	(559,395)	-	488,999
Revaluation	108,366	-	-	-	108,366
	2,060,397	546,363	(700,673)	-	1,906,087

PRIOR YEAR

	Funds brought forward	Income	Expenditure including gains and losses	Transfer	Funds carried forward
GROUP	£	£	£	£	£
Designated	-	-	-	1,450,000	1,450,000
General	981,894	1,643,336	(678,549)	(1,450,000)	496,681
Revaluation	158,366	-	(50,000)	-	108,366
	1,140,260	1,643,336	(728,549)	-	2,055,047

	Funds brought forward	Income	Expenditure including gains and losses	Transfer	Funds carried forward
CHARITY	£	£	£	£	£
Designated	-	-	-	1,450,000	1,450,000
General	988,776	1,594,511	(631,256)	(1,450,000)	502,031
Revaluation	158,366	-	(50,000)	-	108,366
	1,147,142	1,594,511	(681,256)	-	2,060,397

Funds designated in 2018:

- Designated fund of £1,200,000 into research over 5 years.
- Designated fund of £250,000 to pump prime projects over the next 3 years to raise even more funds for our work and for development of the strategic themes of awareness, empowerment and healthcare.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019

21. ANALYSIS OF NET ASSETS

2019

GROUP	Unrestricted £	Designated £	Restricted £	Total £
Tangible fixed assets	150,231	-	-	150,231
Investments	525,259	-	-	525,259
Current assets	476,729	1,308,722	-	1,785,451
Current liabilities	(557,462)	-	-	(557,462)
	594,757	1,308,722	-	1,903,479

CHARITY	Unrestricted £	Designated £	Restricted £	Total £
Tangible fixed assets	150,231	-	-	150,231
Investments	525,259	-	-	525,259
Current assets	465,337	1,308,722	-	1,774,059
Current liabilities	(543,462)	-	-	(543,462)
	597,365	1,308,722	-	1,906,087

PRIOR YEAR

GROUP	Unrestricted £	Designated £	Restricted £	Total £
Tangible fixed assets	150,463	-	-	150,463
Investments	511,790	-	-	511,790
Current assets	617,309	1,450,000	-	2,067,309
Current liabilities	(674,515)	-	-	(674,515)
	605,047	1,450,000	-	2,055,047

CHARITY	Unrestricted £	Designated £	Restricted £	Total £
Tangible fixed assets	150,463	-	-	150,463
Investments	511,790	-	-	511,790
Current assets	611,743	1,450,000	-	2,061,743
Current liabilities	(663,599)	-	-	(663,599)
	610,397	1,450,000	-	2,060,397

22. GOING CONCERN

Financial statements have been prepared on the going concern basis. No material uncertainties exist over the going concern assumption.

23. RELATED PARTIES

During the year staff recharges of £5,136 (2018 - £8,526) were made to RSA Trading Company Limited, as at 31 March 2019 SRUK are due £46,940 (2018 - £45,626) from RSA Trading Company Limited.

All transactions were carried out at arm's length

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019

24. PRINCIPAL SUBSIDIARIES

Company Name	Country	Percentage	Description
RSA Trading Company Limited	United Kingdom	100%	Sale of products to help with the medical conditions of Raynaud's and Scleroderma

The subsidiary was registered in England and Wales with registered number 07869668.

Financial review:	2019	2018
	£	£
Net assets	(2,761)	(5,345)
Income	46,388	57,351
Expenditure	(43,804)	(55,818)
Profit	2,584	1,533

25. OPERATING LEASES

Group and Charity	2019	2018
Operating Leases - Buildings	£	£
Amounts due:		
< 1 year	8,064	8,064
2-5 years	14,112	22,176
Total	22,176	30,240

LEGAL AND ADMINISTRATIVE DETAILS

Trustees:

Christopher Coombe
Kenneth Hicks
Susan Hoare
Professor Jeremy Pearson
Helena Rozga
Professor David G.I. Scott

President:

Professor Dame Carol Black

Vice Presidents:

Professor Christopher Denton
Professor Ariane Herrick

Chief Executive Officer: Senior Management Team:

Sue Farrington
Fatima Sulaiman, David Atkinson, Gemma Cornwell,

Principal Bankers:

NatWest Bank,
1 Upper Market Square, Hanley,
Stoke on Trent,
ST1 1NS

CAF Bank Limited,
25 Kings Hill Avenue, Kings Hill,
West Malling, Kent,
ME19 4JQ

Solicitors:

DLA Piper,
3 Noble Street,
London,
EC2V 7EE

Clyde & Co,
The St Botolph Building,
138 Houndsditch,
London,
EC3A 7AR

Auditors:

Haysmacintyre LLP,
10 Queen Street Place,
London,
EC4R 1AG